Abiomed to Ring NASDAQ Closing Bell, Celebrating Regulatory Progress and Global Leadership in Circulatory Care for Acute Heart Failure Patients.DANVERS, Mass. -- Abiomed, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : ABMD ABMD areal bone mineral density ABMD AEGIS Ballistic Missile Defense (US Navy) ABMD Advanced Ballistic Missile Defense ) today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will ring the closing bell of the NASDAQ Stock Market Nasdaq stock market The first electronic stock market listing over 5000 companies. The Nasdaq stock market comprises two separate markets, namely the Nasdaq National Market, which trades large, active securities and the Nasdaq Smallcap Market that trades emerging growth companies. on December 28, 2006 at 4 pm ET. "Today we commemorate our progress broadening our product portfolio and increasing our global distribution to advance circulatory care for patients in hospital catheterization catheterization Threading of a flexible tube (catheter) through a channel in the body to inject drugs or a contrast medium, measure and record flow and pressures, inspect structures, take samples, diagnose disorders, or clear blockages. labs, intensive care units and surgery suites," said Minogue. "Abiomed now has a full spectrum of patient support technologies including our new Intra-Aortic Balloon, breakthrough Impella technologies, BVS BVS Biblioteca Virtual em Saúde (Brazil) BVS Bureau of Vital Statistics BVS Brethren Volunteer Service (Church of the Brethren) BVS Boston Vegetarian Society (Cambridge, MA) 5000 and AB5000 Circulatory Support Systems and the AbioCor, recently approved by the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. after 25 years of development. This is the world's only fully implantable artificial heart. Looking ahead to 2007, our portfolio of new products, following regulatory progress, is robust and we are excited about our opportunities to improve patient care and drive revenue growth." Highlights from Abiomed's 2006 calendar year included: * Entering pilot studies in the U.S. for the Impella 2.5 and 5.0 technologies. * Receiving approval for the world's only fully implantable artificial heart, the AbioCor, under a Humanitarian Device Exemption. * Receiving 510(k) clearance of a new Intra-Aortic Balloon (IAB (1) See Internet Architecture Board. (2) (Interactive Advertising Bureau, New York, www.iab.net) An industry association founded in 1996 to set standards and guidelines for interactive advertising and marketing. ). * FDA approval of a new Integrated Off-Pump Cannula cannula /can·nu·la/ (kan´u-lah) a tube for insertion into a vessel, duct, or cavity; during insertion its lumen is usually occupied by a trocar. can·nu·la or can·u·la n. pl. system. * Submission for FDA PMA PMA (papillary-marginal-attached), n a system of epidemiologic scoring of periodontal disease devised by Schour and Massler in which the symbols denote the areas involved in gingival inflammation. PMA Progressive muscular atrophy supplement of iPulse combination console platform to support the new IAB, the BVS 5000, the AB5000 and new product introductions in the future. * Improving awareness of recovery as the best option for acute heart failure through evidence-based medicine evidence-based medicine Decision-making 'The use of scientific data to confirm that proposed diagnostic or therapeutic procedures are appropriate in light of their high probability of producing the best and most favorable outcome'. See Meta-analysis. with publications and presentations at multiple medical conferences. With exclusive labeling for recovery on its BVS and AB5000 technologies to rest and recover patients' hearts following an acute event, Abiomed provides physicians with therapeutic flexibility to treat patients with heart failure. In Europe, Abiomed offers the Impella technologies under CE Mark approval. As the world's smallest Ventricular Assist Devices ventricular assist device: see under heart, artificial. (VADs), the Impella technologies have been used to treat more than 800 patients. Abiomed is the global leader in circulatory support for acute (or sudden) heart failure patients. There are approximately 1.1 million patients with acute heart failure each year in the United States and significantly more globally. Abiomed has the highest published recovery rates and recovery is statistically the most likely outcome for acute heart failure patients when placed on support with Abiomed technologies. ABOUT THE NASDAQ CLOSING BELL The NASDAQ Stock Market rings the closing bell at 4 p.m. and the ceremony will be available for viewing through NASDAQ's web cam: http://www.nasdaq.com/reference/marketsite_about.stm, beginning at 3:50 p.m. Viewers can scroll to the bottom of the page to access the MarketSite Live Web cam link. Windows Media Player Digital jukebox software for Windows from Microsoft that plays a variety of audio, video and streaming formats including MP3, WMA, CD audio and MIDI. Starting with Version 6.2 in 1999, the Windows Media Rights Manager was added for securing copyrighted content. is necessary to view the web cam. ABOUT ABIOMED Based in Danvers, Massachusetts, Abiomed, Inc., is a leading developer, manufacturer and marketer of medical products designed to assist or replace the pumping function of the failing heart. Abiomed currently manufactures and sells the AB5000[TM] Circulatory Support System and the BVS([R]) 5000 Biventricular Support System for the temporary support of all patients with failing but potentially recoverable hearts. The Company also developed the AbioCor([R]) Implantable Replacement Heart. In Europe, Abiomed offers the minimally invasive Impella([R]) Circulatory Support System under CE Mark approval. The Impella([R]) 5.0 and 2.5 are investigational devices limited by Federal Law solely to investigational use in the United States. Other Impella devices are not yet available for sale in the United States. For additional information please visit: www.abiomed.com. FORWARD-LOOKING STATEMENTS This Release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the Annual Report filed on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. . Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion